Swine IFN cocktail can reduce mortality and lessen the tissue injury caused by African swine-fever-virus-infected piglets

Front Cell Infect Microbiol. 2024 Dec 3:14:1388035. doi: 10.3389/fcimb.2024.1388035. eCollection 2024.

Abstract

African swine fever (ASF), a highly virulent viral infection, poses a significant threat to the global pig industry. Currently, there are no commercially available vaccines against ASF. While the crucial role of interferon (IFN) in combating viral infections is well-established, its impact on the clinical signs and mortality rates of ASF remains unclear. In this study, swine IFN-α2, IFN-γ, and IFN-λ3 were fused with the Fc segment of immunoglobulin G (IgG) and expressed in mammalian cells (293T), and the antiviral efficacy were detected by VSV-3D4/2 and VSV-PK15 systems. Then, the interferon stimulating genes (ISGs) induced by IFNs-hFc in 3D4/2 cells were determined by qRT-PCR. Also, the preventive potential of the interferon (IFN) cocktail (a mixture of IFNα2-hFc, IFNγ-hFc, and IFNλ3-hFc) were evaluated in vivo by 25-day-old piglets. The results showed that the specific activities of IFNα2-hFc, IFNγ-hFc, and IFNλ3-hFc were 2.46 × 107 IU/mL, 4.54 × 109 IU/mL and 7.54 × 1010 IU/mL, respectively. The IFN-hFc significantly induced the expression of various IFN-stimulated genes (ISGs) in 3D4/2 cells after IFNs-Fc treatment, including IFIT5, Mx1, OASL, ISG12, STAT1, IRF1, PKR, CXCL10, and GBP1. Furthermore, the IFN cocktail treatment reduced the viral load, delayed death, and reduced tissue injury in the piglets infected with ASF virus (ASFV). in conclusion, these results suggest that the IFNs-hFc showed high anti-viral activity, and the IFN cocktail may be potential for the prevention and treatment of ASF.

Keywords: African swine fever; cocktail; interferon; mortality; viral load.

MeSH terms

  • African Swine Fever Virus* / genetics
  • African Swine Fever Virus* / immunology
  • African Swine Fever* / virology
  • Animals
  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Cell Line
  • HEK293 Cells
  • Humans
  • Interferon-gamma / metabolism
  • Interferons*
  • Swine
  • Viral Load

Substances

  • Interferons
  • Antiviral Agents
  • Interferon-gamma

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work is supported by grants from the National Key Research and Development Plan of China (2021YFD1801201).